The HDGF knockout HT29 polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional studies of hepatoma-derived growth factor (HDGF) in human colorectal adenocarcinoma. This gene-disrupted model provides a loss-of-function system to investigate HDGF-dependent cellular processes, including proliferation, survival, and metastatic progression. The polyclonal pool offers a heterogeneous knockout background, facilitating population-level analyses of HDGF deficiency without clonal selection artifacts.
The HT29 cell line originates from a primary colorectal adenocarcinoma of a 44-year-old female patient and serves as a canonical intestinal epithelial cell model for colorectal cancer research. HT29 cells exhibit polarized epithelial morphology and retain key signaling network dependencies, including elevated MAPK/ERK and PI3K/AKT pathway activities, making them particularly suitable for dissecting oncogenic mechanisms driven by growth factors such as HDGF.
HDGF is a nuclear and secreted growth factor that promotes cell proliferation, angiogenesis, and tumorigenesis. Mechanistically, HDGF binds to cell surface receptors such as nucleolin to stimulate the MAPK/ERK and PI3K/AKT cascades; downstream, ERK1/2 and AKT phosphorylate targets that upregulate Cyclin D1, Bcl-2, and VEGF, while also modulating MMP-2 and MMP-9 to enhance invasion. In the nucleus, HDGF functions as a transcriptional co-activator interacting with importin ??, PCNA, and p53. Its activity is induced by upstream stimuli including EGF, serum, and hypoxia, and it feeds into the NF-??B pathway via IKK to sustain pro-survival signaling. This knockout model disrupts these interconnected signaling modules, enabling dissection of HDGF??s role in signal transduction.
In the context of colorectal adenocarcinoma, HDGF overexpression correlates with aggressive disease, making the HDGF knockout HT29 polyclonal cells a valuable tool for dissecting tumor-intrinsic dependencies. Loss of HDGF in HT29 cells is expected to attenuate MAPK/ERK-driven proliferation and PI3K/AKT-mediated survival, thereby reducing oncogenic traits such as anchorage-independent growth, migration, and resistance to apoptosis. The polyclonal population captures a spectrum of editing outcomes, reflecting more closely the heterogeneity of solid tumors, and is ideal for bulk assays that evaluate pathway rewiring, drug sensitivity, and metastatic potential in colorectal cancer.
Researchers can use this knockout model for functional assays such as western blotting for signaling protein phosphorylation, RT-qPCR for transcriptional changes in Cyclin D1, Bcl-2, and MMPs, and MTT or CCK-8 proliferation assays. Migration and invasion can be assessed by Transwell assays, and apoptosis by Annexin V staining. The cells are applicable to tumor xenograft studies and drug screening for HDGF inhibitors. Co-immunoprecipitation and immunofluorescence can resolve protein interactions and localization. For further details, contact Ascent Research.
